



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/806,568	07/30/2001	Wataru Morikawa	20-48418	2810
2292	7590	04/04/2006	EXAMINER	
BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747				HARRIS, ALANA M
ART UNIT		PAPER NUMBER		
		1643		

DATE MAILED: 04/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Interview Summary	Application No.	Applicant(s)	
	09/806,568	MORIKAWA ET AL.	
	Examiner	Art Unit	
	Alana M. Harris, Ph.D.	1643	

All participants (applicant, applicant's representative, PTO personnel):

(1) Alana M. Harris, Ph.D. (3) _____.

(2) Thomas J. Siepmann, Ph.D. (4) _____.

Date of Interview: 21 March 2006.

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
If Yes, brief description: _____.

Claim(s) discussed: 1,3,11 and 15.


Identification of prior art discussed: Gately et al. (Cancer Research 56: 4887-4890, November 1, 1996).

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.



ALANA M. HARRIS, PH.D.
PRIMARY EXAMINER
03/21/2006

Examiner Note: You must sign this form unless it is an attachment to a signed Office action.

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Dr. Siepmann, Applicants' representative and the Examiner discussed proposed claim amendments to claim 1. Dr. Siepmann pointed out Table 1 on page 4889 of Gately noting the aspartic protease inhibitor, pepstatin did not have any inhibitory activity against the protein of Gately, which is in contrast to Applicants' enzyme protein. Participants also discussed the mechanistic differences between aspartic protease inhibitors and serine protease inhibitors. Gately's enzyme was inhibited by serine proteinases, whereas Applicants' representative states the claimed product was not (see Figure 5 and the Declaration submitted 07/22/2004). The Examiner stated to Applicants' representative she would consider the amendments to claim 1, as well as well as all supporting documents making the distinction between the claimed product and that of Gately.. .